Jeffrey Stuart Pollack, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 6044 Harding Hwy, Mays Landing, NJ 08330 Phone: 609-625-9146 Fax: 609-625-7405 |
Dr. Michael Frank Lurakis, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1161 Route 50, Mays Landing, NJ 08330 Phone: 609-625-7116 Fax: 609-625-3275 |
Dr. Arnold Saguin Bacarro, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 5429 Harding Hwy, Suite 301, Mays Landing, NJ 08330 Phone: 609-625-4430 Fax: 609-625-4436 |
Dr. Augustine Aigbovbioise Unuigbe, M.D Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4622 Black Horse Pike, Suite 101, Mays Landing, NJ 08330 Phone: 609-705-8143 Fax: 609-837-0144 |
News Archive
Triple-negative breast cancer is as bad as it sounds. The cells that form these tumors lack three proteins that would make the cancer respond to powerful, customized treatments. Instead, doctors are left with treating these patients with traditional chemotherapy drugs that only show long-term effectiveness in 20 percent of women with triple-negative breast cancer.
Dartmouth engineers and radiologists are developing new approaches for an emerging technique in diagnostic imaging for breast cancer-MRI with near-infrared spectroscopy as reported in the journal Academic Radiology, February 2014.
A new study indicates that the social difficulties faced by many adolescent and young adult cancer survivors often persist for years after their diagnosis.
Fewer American adults are smoking cigarettes, according to a new Vital Signs report from the Centers for Disease Control and Prevention. Also, daily smokers are smoking fewer cigarettes each day, it says.
Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.
› Verified 9 days ago